Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Bleomycin Sulphate
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : National Cancer Institute
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 01, 2017
Lead Product(s) : Bleomycin Sulphate
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : National Cancer Institute
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Bleomycin Sulphate
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Australian and New Zealand Urogenital and Prostate Cancer Trials Group | Cambridge University Hospitals NHS Foundation Trust | Cancer Trials Ireland | Children's Oncology Group | Dana-Farber Cancer Institute | University of Southern California
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 21, 2015
Lead Product(s) : Bleomycin Sulphate
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Australian and New Zealand Urogenital and Prostate Cancer Trials Group | Cambridge University Hospitals NHS Foundation Trust | Cancer Trials Ireland | Children's Oncology Group | Dana-Farber Cancer Institute | University of Southern California
Deal Size : Inapplicable
Deal Type : Inapplicable